U.S. Food and Drug Administration Approves Brentuximab Vedotin for Cutaneous T-cell Lymphoma
New York, NY (November 9, 2017) –The U.S. Food and Drug Administration (FDA) announced it…
Lymphoma News
U.S. Food and Drug Administration Approves Acalabrutinib for Mantle Cell Lymphoma
New York, NY (October 31, 2017) –The U.S. Food and Drug Administration (FDA) announced it…
FDA Approves Copanlisib for Relapsed Indolent Follicular Lymphoma
New York, NY (September 14, 2017) – The U.S. Food and Drug Administration (FDA) announced…
FDA Approves Ibrutinib to Treat Chronic Graft Versus Host Disease
New York, NY (August 3, 2017) – New York, NY – The U.S. Food and…
FDA Approves Subcutaneous Rituximab for Treatment of Various Lymphomas
New York, NY (June 5, 2017) – The U.S. Food and Drug Administration (FDA) announced…
FDA Approves Pembrolizumab (KEYTRUDA®) for Classical Hodgkin Lymphoma
New York, NY (March 14, 2017) – The U.S. Food and Drug Administration (FDA) announced…
Lymphoma Research Foundation Publishes White Paper Outlining Key Issues From Oral Therapy Workshop
Lymphoma Research Foundation publishes White Paper to outline key issues discussed during Oral Therapies workshop…
Stay informed with news, alerts and other resources.
